Trial Profile
A multicenter, prospective, open-label, non-controlled clinical trial to assess the efficacy and safety of Immune Globuline (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in patients with Myasthenia Gravis exacerbations
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Registrational; Therapeutic Use
- Sponsors Grifols
- 10 May 2018 Status changed from recruiting to completed.
- 29 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 29 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.